Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2...
Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position...
Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2...
Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position...
Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
